Bioqube Ventures is a specialist life sciences investment firm. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.

Bioqube Ventures was incorporated by Debora Dumont and Nico Vandervelpen in 2015 with the sole aim to invest in groundbreaking and innovative therapeutics. In 2016, Bioqube launched its first investment vehicle on the Janssen campus in Beerse. 

In 2020, Bioqube launched its second investment vehicle "Bioqube Factory Fund I - BFF I" 

… An early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.

… A fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. 

… A hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.  

BFF I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (“EFSI”) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.

Venture Capital

Life Sciences

Biotechnology

Bioqube Ventures

Bioqube Ventures' headquarters in Brussels, Belgium

Debora Dumont

Jacques Mizrahi

Tom Heyman

Clement Salque

Krishna Polu

Nico Vandervelpen

Dirk Reyn

Description

People (5)

Debora Dumont

Joris De Maeyer

Nico Vandervelpen

Alexander Demoulin

Clement Salque

Jobs